Arsenal Bio

Executive Summary

Arsenal Bio is a private biotechnology company headquartered in South San Francisco, focused on engineering next-generation cell therapies for solid tumors. Founded in 2019, the company integrates CRISPR gene editing, synthetic biology, and computational tools to create 'smart' T-cells that exhibit enhanced persistence, tumor-homing, and resistance to immunosuppression. This approach aims to overcome the limitations of current cell therapies, which have shown limited efficacy in solid cancers. Arsenal Bio has raised $220 million in total funding and employs between 200 and 500 people. The company is currently in Phase 1 clinical development, with its lead candidate targeting multiple solid tumor indications. The platform's modular design allows for rapid iteration and potential expansion into other cancer types. While still early-stage, Arsenal Bio's robust financial backing and innovative technology position it as a notable player in the cell therapy space. However, clinical validation remains pending, and the competitive landscape is intense.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim data for lead solid tumor candidate60% success
• Q4 2026IND filing for second pipeline candidate70% success
• Q2 2026Strategic partnership or licensing deal with a major pharma50% success